No Data Available
Gland Pharma Ltd.
- Open2,390.00
- High2,394.00
- Low2,320.00
- Prev Close2,366.20
- Volume1,50,380
- VWAP(₹)2,365.28
Insights
Board Meeting on Jan 22, 2021
Meeting Agenda: Quarterly Results. Please add to watchlist to track closely.Contingent Liabilities Coverage
Company has sufficient cash reserves to pay off its contingent liabilities. (Source: Standalone Financials)Beating 3 Yr Revenue CAGR
Company's annual revenue growth of 30.17% outperformed its 3 year CAGR of 22.13%. (Source: Standalone Financials)Employee & Interest Expense
Company has spent less than 1% of its operating revenues towards interest expenses and 10.54% towards employee cost in the year ending Mar 31, 2020. (Source: Standalone Financials)
Found Insights useful?
Key Metrics
- PE Ratio(x)-
- EPS - TTM(₹)0.00
- MCap(₹ Cr.)0.00
- MCap Rank87
- PB Ratio(x)0.00
- Div Yield(%)0.00
- Face Value(₹)0.00
- 52W High(₹)2,508.55
- 52W Low(₹)1,500.00
- MCap/Sales0.00
- Beta(1 Month)-
- BV/Share(₹)0.00
Returns
- 1 Day-1.3%
- 1 Month4.9%
- 3 MonthsN.A.
- 1 YearN.A.
- 3 YearsN.A.
- 5 YearsN.A.
Gland Pharma News & Analysis
Financials
Beating 3 Yr Revenue CAGR
Company's annual revenue growth of 30.17% outperformed its 3 year CAGR of 22.13%. (Source: Standalone Financials)Employee & Interest Expense
Company has spent less than 1% of its operating revenues towards interest expenses and 10.54% towards employee cost in the year ending Mar 31, 2020. (Source: Standalone Financials)
Annual FY 2020 FY 2019 FY 2018 Total Revenue 2,772.41 2,129.77 1,668.73 Total Revenue Growth (%) 30.17 27.63 10.31 Total Expenses 1,779.54 1,423.41 1,167.17 Total Expenses Growth (%) 25.02 21.95 24.87 Profit after Tax (PAT) 772.86 451.91 321.11 PAT Growth (%) 71.02 40.73 -22.38 Operating Profit Margin (%) 37.97 34.72 31.21 Net Profit Margin (%) 29.35 22.10 19.82 Basic EPS (₹) 49.88 29.16 211.75 Contingent Liabilities Coverage
Company has sufficient cash reserves to pay off its contingent liabilities. (Source: Standalone Financials)
Annual FY 2020 FY 2019 FY 2018 Total Assets 4,086.04 3,522.58 2,928.34 Total Assets Growth (%) 16.00 20.29 18.38 Total Liabilities 439.80 660.47 517.92 Total Liabilities Growth (%) -33.41 27.52 34.90 Total Equity 3,646.24 2,862.11 2,410.42 Total Equity Growth (%) 27.40 18.74 15.34 Current Ratio (x) 7.93 4.43 4.89 Total Debt to Equity (x) 0.00 0.00 0.00 Contingent Liabilities 134.54 171.60 51.24 All figures in Rs Cr, unless mentioned otherwise
Increase in Cash from Investing
Company has used Rs 766.08 cr for investing activities which is an YoY increase of 143.87%. (Source: Standalone Financials)
Annual FY 2020 FY 2019 FY 2018 Net Cash flow from Operating Activities 700.94 185.06 201.93 Net Cash used in Investing Activities -766.08 -314.14 -358.84 Net Cash flow from Financing Activities -6.87 -2.93 -3.59 Net Cash Flow -66.91 -136.44 -160.24 Closing Cash & Cash Equivalent 169.50 236.40 372.84 Closing Cash & Cash Equivalent Growth (%) -28.30 -36.59 -30.06 Total Debt/ CFO (x) 0.01 0.03 0.03 All figures in Rs Cr, unless mentioned otherwise
Annual FY 2020 FY 2019 FY 2018 Return on Equity (%) 21.19 15.78 13.32 Return on Capital Employed (%) 26.83 23.74 19.83 Return on Assets (%) 18.91 12.82 10.96 Interest Coverage Ratio (x) 139.24 199.41 122.59 Asset Turnover Ratio (x) 64.44 58.03 55.31 Price to Earnings (x) - - - Price to Book (x) - - - EV/EBITDA (x) - - - EBITDA Margin (%) 41.56 38.73 36.04
Found Financials useful?
Technicals
No Data Available
R1 - Pivot -
S1 - R2 - S2 - R3 - S3 - 5 Days 14 Days 28 Days - - -
Peers
- 1D
- 1W
- 1M
- 3M
- 6M
- 1Y
- 5Y
Choose from Peers
Choose from Stocks
Mutual Funds Ownership
No Data Available
Top Searches
Corporate Actions
No Data Available
No Data Available
No Data Available
No Data Available
No Data Available
No Data Available
No Data Available
About
Gland Pharma Ltd., incorporated in the year 1978, is a Small Cap company (having a market cap of Rs .00 Crore) operating in Pharmaceuticals sector.
Gland Pharma Ltd. key Products/Revenue Segments include Pharmaceuticals which contributed Rs 2321.96 Crore to Sales Value (88.17 % of Total Sales), Sale of services which contributed Rs 249.82 Crore to Sales Value (9.48 % of Total Sales) and Export Incentives which contributed Rs 61.46 Crore to Sales Value (2.33 % of Total Sales)for the year ending 31-Mar-2020.
For the quarter ended , the company has reported a Standalone sales of Rs Crore, unchanged .00 % from last quarter Sales of Rs Crore and unchanged .00 % from last year same quarter Sales of Rs Crore Company has reported net profit after tax of Rs Crore in latest quarter.
The company’s top management includes . Company has S R Batliboi & Associates LLP as its auditors. As on 31-12-2020, the company has a total of 163,282,823 shares outstanding.
About Gland Pharma
Gland Pharma Ltd., incorporated in the year 1978, is a Small Cap company (having a market cap of Rs .00 Crore) operating in Pharmaceuticals sector. Show More
Industry
Key Indices Listed On
S&P BSE IPO Index
Address
Sy.No. 143-148, 150 & 151,Near Gandi Maisamma �X� Roads, D.P. Pally,Hyderabad, Telangana - 500043
Executive Leadership
No Data Available
Auditors
Gland Pharma Share Price Update
Gland Pharma Ltd. share price moved down by -1.30% from its previous close of Rs 2,366.20. Gland Pharma Ltd. stock last traded price is 2,335.55
Share Price | Value |
---|---|
Today/Current/Last | 2,335.55 |
Previous Day | 2,366.20 |
Trending in Markets
DATA SOURCES: TickerPlant (for live BSE/NSE quotes service) and Dion Global Solutions Ltd. (for corporate data, historical price & volume, F&O data). Sensex & BSE Quotes and Nifty & NSE Quotes are real-time and licensed from BSE and NSE respectively. All timestamps are reflected in IST (Indian Standard Time).
DISCLAIMER: Any and all content on this website including tools/analysis is provided to you only for convenience and on an “as-is, as- available” basis without representation and warranties of any kind. The content and any output of such tools/analysis is for informational purposes only and should not be relied upon or construed as an investment advice or guarantee for any specific performance/returns advice or considered as recommendation for the purchase or sale of any security or investment. You are advised to exercise caution, discretion and independent judgment with regards to the same and seek advice from professionals and certified experts before taking any decisions.
By using this site, you agree to the Terms of Service and Privacy Policy.